A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. 1989

E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
Department of Internal Medicine, University of Michigan, Ann Arbor.

To evaluate the coronary thrombolytic efficacy of tissue plasminogen activator (t-PA) and early intravenous heparin, 134 patients with acute myocardial infarction were randomly assigned to combination therapy or t-PA only. At a median of 2.78 hours from symptom onset, 64 patients received both t-PA (1.5 mg/kg/4 hr) and a bolus of 10,000 units heparin, whereas 70 patients received t-PA alone at the same dose. All patients underwent coronary angiography 90 minutes after initiation of therapy to determine infarct vessel patency status, after which time the control group patients were eligible to receive heparin. Baseline demographic and angiographic characteristics were similar for the groups. Infarct vessel patency was 50 of 63 (79%) for combination t-PA and heparin and 54 of 68 (79%) for t-PA alone. Bleeding complications, as reflected by need for transfusion, were similar in the two groups: 13% in the patients treated with t-PA and heparin compared with 18% in patients treated with t-PA only (p = 0.53). The only intracranial hemorrhage in the trial occurred in a patient initially treated without heparin. Fibrinogen at 50 minutes after therapy was 32% decreased from baseline for the t-PA and heparin-treated patients compared with a 39% decrease in the control group. Predischarge left ventricular ejection fraction was similar for the two groups: 49.0 +/- 10.1% versus 50.2 +/- 11.9% for combined versus t-PA only therapy, respectively. We conclude that early intravenous heparin does not facilitate the fibrinolytic effect of t-PA at the doses tested.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000792 Angiography Radiography of blood vessels after injection of a contrast medium. Arteriography,Angiogram,Angiograms,Angiographies,Arteriographies
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
April 1992, American heart journal,
E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
February 1991, Journal of the American College of Cardiology,
E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
June 1989, Journal of the American College of Cardiology,
E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
June 1987, Journal of the American College of Cardiology,
E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
February 1987, Circulation,
E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
August 1991, Zhonghua xin xue guan bing za zhi,
E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
September 1991, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
December 1987, The New England journal of medicine,
E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
November 1985, Lancet (London, England),
E J Topol, and B S George, and D J Kereiakes, and D C Stump, and R J Candela, and C W Abbottsmith, and L Aronson, and A Pickel, and J M Boswick, and K L Lee
January 2017, American journal of therapeutics,
Copied contents to your clipboard!